



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/046,313	01/16/2002	Akihiro Yokoyama	218203US0	2679
22850	7590	02/18/2004	EXAMINER	
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. 1940 DUKE STREET ALEXANDRIA, VA 22314			SPIEGLER, ALEXANDER H	
		ART UNIT	PAPER NUMBER	1637

DATE MAILED: 02/18/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/046,313	YOKOYAMA ET AL.
	Examiner	Art Unit
	Alexander H. Spiegler	1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 03 December 2003.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-8 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-8 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____ .	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: _____ .

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claim 1, drawn to an oligonucleotide for detection of *Salmonella* toxin gene *invA* mRNA, classified in class 536, subclass 23.1, for example.
 - II. Claim 2, drawn to an oligonucleotide for detection of *Salmonella* toxin gene *stn* mRNA, classified in class 536, subclass 23.1, for example.
 - III. Claims 3 and 5-8, drawn to a process of amplifying *Salmonella* gene *invA* mRNA, classified in class 435, subclass 91.51, for example.
 - IV. Claims 4-8, drawn to a process of amplifying *Salmonella* gene *stn* mRNA, classified in class 435, subclass 91.51, for example.

Further Restriction

2. The claims of Group I-IV are drawn to a multitude of nucleic acids, and methods that use these nucleic acids. Each of the different nucleic acids are independent and distinct because no common structural or functional properties are shared, as each nucleic acid has a different structure, as evidenced by their unique structure referred to as a SEQ ID NO, and function differently as each nucleic acid will bind to a specific nucleic acid segment. Accordingly, these claims are subject to restriction under 35 U.S.C. § 121.

Upon election of one of Groups I-IV, Applicant is additionally required to elect a single nucleic acid (e.g., Applicants must elect one SEQ ID NO). For example, Applicants could elect Group I, and SEQ ID NO: 1. However, it is noted, if Applicants elect Group III, Applicants may elect a single sequence from SEQ ID NOS: 1-12 and a single sequence from

Art Unit: 1637

SEQ ID NOS: 19-23 for examination. Likewise for Group IV, wherein if Group IV is elected, Applicants may elect a single nucleic acid sequence from SEQ ID NOS: 13-18 and a single sequence from SEQ ID NOS: 24-27. See MPEP 803.04. This requirement is not to be construed as a requirement for an election of species, since each of the compounds is not a member of a single genus of invention, but constitutes an independent and patentably distinct invention.

Should applicant traverse on the ground that the nucleic acids are not patentably distinct, applicant should submit evident or identify such evidence now of record showing the species to be obvious variant or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other inventions.

3. The inventions are distinct, each from the other because of the following reasons:

A) Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the different inventions are an oligonucleotide that specific binds to *Salmonella* gene *invA* mRNA (Group I), and an oligonucleotide that specific binds to *Salmonella* gene *stn* mRNA, which are two different chemical entities having differing biochemical structures (SEQ ID NOS), modes of operation, functions (binding to different genes), and effects. Furthermore, Group I would require searching in areas unrelated to *Salmonella* gene *stn*, and as such, would require an undue burden on the examiner if not restricted.

Art Unit: 1637

B) Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the oligonucleotide of Group I can be used in a materially different process, such as in a hybridization assay.

C) Inventions I and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the oligonucleotide of Group I is not disclosed as capable of use in the method of Group IV. Furthermore, the function of Group IV is to amplify the *Salmonella* gene *stn*, whereas the oligonucleotide of Group I functions to bind to *Salmonella* gene *invA*, and therefore, the modes of operation, functions, and effects of these Groups are different. In addition, Group I would require searching in areas unrelated to *Salmonella* gene *stn*, and as such, would require an undue burden on the examiner if not restricted.

D) Inventions II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the oligonucleotide of Group II is not disclosed as capable of use in the method of Group III. Furthermore, the function of Group III is to amplify the *Salmonella* gene *invA*, whereas the oligonucleotide of Group I functions to bind to *Salmonella* gene *stn*, and therefore, the modes of operation, functions, and effects of these Groups are different. In addition, Group II would

Art Unit: 1637

require searching in areas unrelated to *Salmonella* gene *invA*, and as such, would require an undue burden on the examiner if not restricted.

E) Inventions II and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the oligonucleotide of Group II can be used in a materially different process, such as in a hybridization assay.

F) Inventions III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the inventions are directed to methods having different method steps, starting materials, and goals. Group III is drawn to a process of amplifying *Salmonella* gene *invA*, whereas Group IV is drawn to a process of amplifying *Salmonella* gene *stn*. Accordingly, because they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects, these Groups are unrelated. Furthermore, Group III would require searching in areas unrelated to *Salmonella* gene *stn*, and as such, would require an undue burden on the examiner if not restricted.

4. Because these inventions are distinct for the reasons given above and have acquired a different status in the art as demonstrated by their different classification and recognized divergent subject matter and because inventions I-IV require different searches that are not co-

Art Unit: 1637

extensive, examination of these distinct inventions would pose a serious burden on the examiner and therefore restriction for examination purposes as indicated is proper.

5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See “Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b),” 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does

Art Unit: 1637

not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alexander H. Spiegler whose telephone number is (571) 272-0788. The examiner can normally be reached on Monday through Friday, 7:00 AM to 3:30 PM.

If attempts to reach the examiner are unsuccessful, the primary examiner in charge of the prosecution of this case, Carla Myers, can be reached at (571) 272-0747. If attempts to reach Carla Myers are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at (571) 272-0782. The fax number for the organization where this application or proceeding is assigned is (703) 872-9306.

Alexander H. Spiegler
February 10, 2004

Carla J. Myers
CARLA J. MYERS
PRIMARY EXAMINER